GREM1 and coronary artery disorder: These findings suggest that GREM1 can compel aging hMPCs to adopt a more robust phenotype, and that GREM1 is a potential therapeutic target for improving the efficacy of cardiac mesenchymal progenitor cell therapy for ischemic heart disease in the future.